Brassesco María Sol, Xavier Danilo Jordão, Camparoto Marjori Leiva, Montaldi Ana Paula, de Godoy Paulo Roberto D'Auria Vieira, Scrideli Carlos Alberto, Tone Luiz Gonzaga, Sakamoto-Hojo Elza Tiemi
Departamento de Puericultura e Pediatria, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 14040-901 São Paulo, Brazil.
J Biomed Biotechnol. 2011;2011. doi: 10.1155/2011/230481. Epub 2010 Aug 31.
Contemporary anticancer therapies have largely improved the outcome for children with cancer, especially for Acute Lymphoblastic Leukemia (ALL). Actually, between 78% and 85% of patients achieve complete remission and are alive after 5 years of therapy completion. However, as cure rates increase, new concerns about the late effects of genotoxic treatment emerge, being the risk of developing secondary neoplasias, the most serious life-threatening rising problem. In the present paper, we describe and review the cytogenetic findings in peripheral lymphocytes from ALL survivors, and discuss aspects associated to the occurrence of increased chromosome rearrangements in this growing cohort.
当代抗癌疗法在很大程度上改善了癌症患儿的治疗效果，尤其是急性淋巴细胞白血病（ALL）患儿。实际上，78%至85%的患者实现了完全缓解，并且在完成治疗5年后仍存活。然而，随着治愈率的提高，对基因毒性治疗晚期效应的新担忧出现了，其中最严重的危及生命的问题是发生继发性肿瘤的风险。在本文中，我们描述并回顾了ALL幸存者外周淋巴细胞的细胞遗传学发现，并讨论了与这一不断增加的队列中染色体重排增加的发生相关的方面。
